Lyell Immunopharma
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $8 | $7 | $11 | $34 |
Gross Profit | 8 | 7 | 11 | 34 |
EBITDA | -42,562 | -53,926 | -57,640 | -45,825 |
EBIT | -45,697 | -57,367 | -62,666 | -50,505 |
Net Income | -42,684 | -52,195 | -191,935 | -44,583 |
Net Change In Cash | 8 | 7 | 11 | 34 |
Free Cash Flow | -34,626 | -54,984 | -47,286 | -35,101 |
Cash | 98,804 | 120,328 | 105,597 | 100,299 |
Basic Shares | 14,793 | 295,098 | 266,539 | 256,309 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $61 | $130 | $84,683 | $10,650 |
Gross Profit | 61 | 130 | 68,216 | -3,885 |
EBITDA | -200,643 | -226,758 | -166,651 | -199,942 |
EBIT | -220,274 | -247,008 | -183,118 | -214,477 |
Net Income | -342,994 | -234,632 | -4,754 | -285,501 |
Net Change In Cash | 61 | 130 | 84,683 | 10,650 |
Cost of Revenue | 153,422 | |||
Free Cash Flow | -162,858 | -166,380 | -193,831 | -191,753 |
Cash | 105,597 | 145,647 | 123,554 | 293,828 |
Basic Shares | 261,480 | 250,983 | 247,080 | 242,738 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$2.89 |
2025-03-31 | -$0.17 |
2024-12-31 | -$0.44 |
2024-09-30 | -$0.19 |
